Latest news with #CCDC
Business Times
6 days ago
- Business
- Business Times
Building neighbourhoods and advancing innovation
IN 1992, a newly incorporated construction company quietly broke ground in Singapore. Its first project, Sentosa's now-defunct Volcano Theme Park, marked the beginning of a long and growing commitment to the citystate. Thirty-three years on, China Construction (South Pacific) Development Co Pte Ltd (CCDC) has firmly established itself as a key player in Singapore's urban story, credited with building 82,691 homes, major national infrastructure, and a reputation for quality, safety and sustainability. Now one of Singapore's leading contractors with the highest Building and Construction Authority (BCA) builder grade (A1) and over 280 industry awards, CCDC's growth has closely tracked Singapore's development. Beyond the numbers, however, the company measures success by the lives and communities shaped by its work. From its early days, CCDC has responded to Singapore's priorities. After its private residential debut in 1994, the company swiftly moved into the public housing space, winning its first HDB project in Bukit Batok that same year. Since then, it has delivered 48,984 HDB flats and 33,707 private homes. Today, one in 20 people here lives in a home built by CCDC. Beyond housing, the company has extended its reach across the built environment, from educational institutions, commercial centres and healthcare facilities to transport infrastructure and even water management. Key milestones include the construction of Republic Polytechnic's Woodlands campus (2003-2006), which featured varied structural designs; the Canberra MRT Station (2015-2019), a technically challenging project that earned multiple safety and design awards; and the Tuas Water Reclamation Plant, its first foray into water infrastructure. The developer's current portfolio includes high-profile, complex projects like Bukit Canberra, an integrated sports and community hub, and CanningHill Piers mixed development, its first large-scale, high-end project. Bukit Canberra, an integrated sports and community hub. Responding to changing aspirations CCDC's steady growth reflects not just Singapore's development needs, but also the evolving aspirations of its people. Singaporeans today are placing greater emphasis on quality of life, sustainability, and smart living, moving beyond traditional goals like material success or homeownership. This shift has created stronger demand for thoughtfully designed technology-enabled spaces that enhance everyday living in a modern urban environment. This is visible in projects such as Oasis Terraces, a lushly vegetated waterfront hub in Punggol that integrates healthcare, retail, residential and transport within a green ecosystem. The development received acclaim locally and abroad, including an award at the World Architecture Festival. CCDC has also been an early adopter of green building standards. It has built more than 70 BCA Green Mark-certified projects since 2006, many of which exceed minimum regulatory requirements. These include green rooftops and innovative natural lighting systems, all designed to minimise environmental impact while improving user comfort. By prioritising and practising Green Mark building standards, CCDC proactively implements environment friendly construction methodologies, materials and systems. Harnessing technology for transformation Key to CCDC's growth has been its push to modernise construction through technology. As early as 2014, it set up a dedicated Building Information Modelling (BIM) team and today deploys over 200 BIM specialists across its projects. The team works on full-scale 2D to 6D models to enable more precise planning and resource management, as it seeks to 'build twice and build wise'. On the prefabrication front, CCDC has led the local adoption of Prefabricated Prefinished Volumetric Construction (PPVC) and Design for Manufacturing and Assembly (DfMA). Its Lake Grande project was Singapore's first reinforced concrete condominium using PPVC, significantly reducing build time and site waste. At Bulim Square, another ongoing project, the company is employing an advanced drilling robot, prefabricated MEP (Mechanical, Electrical, and Plumbing) modules, and an integrated digital management platform. At Bulim Square, another ongoing project, the company is employing an advanced drilling robot, prefabricated modules, and an integrated digital management platform. The drilling robot showcased its precision and efficiency, completing complex tasks with minimal human intervention, thus significantly reducing labour costs and project timelines. According to CCDC, these technologies are not just about speed, they support higher build quality, better safety outcomes and reduced carbon emissions. The company is also piloting smart micro-grid systems and battery energy storage technologies, while exploring AI-assisted inspection and construction automation. These initiatives align with Singapore's Smart Nation and Green Plan goals. Investing in people CCDC's belief in building well extends to its people. With over 1,600 employees in Singapore, the company places strong emphasis on local hiring, skills development and workplace inclusion. Today, 94 per cent of its core management team are Singaporeans or permanent residents. To equip its staff with the right qualifications and skills, the company implements a comprehensive annual training plan that includes both internal and external programmes. These initiatives aim to help employees stay current with industry standards and effectively support the increasing demands of CCDC's construction projects. The company also offers dual career tracks for professional and leadership development. CCDC's active emphasis on safety and quality is also supported through dedicated training sessions, interactive site activities, and internal knowledge-sharing platforms like the 'EasyLearn' series. Community at the core Looking beyond the bottom line, CCDC has invested heavily in building communities. This includes social outings for migrant workers, such as a recent Gardens by the Bay trip in partnership with The Salvation Army, and friendly badminton tournaments that encourage camaraderie and inclusion on site. At Riviera MRT station, one of CCDC's ongoing projects, a vibrant community mural now brightens the space, featuring 18 artworks created by young artists from Greendale Primary, Horizon Primary, and the Punggol Shore neighbourhood. The company's commitment to community care extends even after construction is completed. Its Building Service Centres, for instance, handle post-handover support for HDB developments, reflecting its focus on resident satisfaction. In 2024, CCDC received the HDB Excellence Service Award for its work at Tampines GreenCourt and Woodleigh Village. Riviera MRT project. 'Passionate customer service is the cornerstone of our success. We emphasise empathy, active listening, and timely solutions, with the goal of building meaningful connections with residents,' says a CCDC spokesperson. Building ties across borders CCDC's story is also about cross-cultural connection. As a wholly owned subsidiary of China State Construction Engineering Corporation (CSCEC), CCDC has served as a ground-level bridge between Singapore and China for over three decades. 'We believe that every project is not just a structure, but a bridge between people, ideas, and cultures. Delivering high-quality work, acting responsibly, and building lasting relationships is a meaningful way to support the broader Singapore-China partnership on the ground,' says the company spokesperson. This includes adapting innovations from China for local use and ensuring Singapore standards and culture are integrated into every delivery. The company also works closely with local suppliers and industry partners, promoting local procurement and inclusive business practices. Looking ahead, CCDC's priorities remain aligned with Singapore's national goals over the next decade. The company plans to deepen its role in key sectors such as healthcare, transport and green infrastructure, areas identified in the Singapore Green Plan 2030. 'While we have played an active role in Singapore's residential and public construction landscape, we are now placing greater emphasis on landmark projects, which reflect the country's evolving infrastructure needs,' says the CCDC spokesperson. 'By introducing innovative products from our Group and adapting them to local needs, we aim to provide solutions that are sustainable, efficient, and suited to Singapore's urban vision.'
Hans India
02-08-2025
- Health
- Hans India
AIIMS-led study shows two-medicine combination therapy effective in controlling high BP
Using a single pill comprising two blood pressure medicines is a safe and highly effective way to treat hypertension among South Asians, particularly Indians, finds a study led by the All India Institute of Medical Sciences (AIIMS), New Delhi. The study, in partnership with the Centre for Chronic Disease Control (CCDC) and Imperial College London, UK, compared three widely used drug combinations: amlodipine plus perindopril, amlodipine plus indapamide, and perindopril plus indapamide. The first randomised trial to test three different two-drug combination pills among South Asians involved over 1,200 patients with uncontrolled hypertension across 32 hospitals in India. 'All three combinations worked equally well in reducing blood pressure and were safe for patients,' revealed the study, published in the journal Nature Medicine. The findings showed that either of the two-drug combinations led to a significant drop in blood pressure after 6 months -- by around 14/8 mmHg when measured over 24 hours and about 30/14 mmHg in clinic settings. 'Nearly 70 per cent of patients got their blood pressure under control, a huge improvement over the current national average. And the pills were safe and easy to use. This study gives clear guidance for better hypertension care,' said Dr Ambuj Roy, Professor of Cardiology at AIIMS Delhi. 'This study shows that a single daily pill with two drugs can be a simple and powerful way to manage blood pressure in Indian and South Asian patients,' said Dr Dorairaj Prabhakaran, Executive Director of CCDC. High blood pressure (hypertension) is the leading risk factor for death worldwide and affects over 300 million people in India alone. Treating it early and effectively can prevent heart attacks, strokes, and kidney failure. Doctors often recommend starting with two medications in one pill to control blood pressure better and help patients stick to treatment. But until now, no large study had tested which combinations worked best for South Asians, who make up a quarter of the world's population. The results revealed that nearly 70 per cent of patients with any of the dual drug therapy reached the recommended blood pressure target of below 140/90 mmHg -- five times higher than India's current average control rate. Less than 3 per cent of patients reported side effects serious enough to stop treatment. 'These findings can help guide doctors and policymakers. If added to India's list of essential medicines and made available at primary health centres, these pills could greatly improve blood pressure control in the country,' Prabhakaran said.
Business Standard
30-07-2025
- Health
- Business Standard
TOPSPIN Study by the Centre for Chronic Disease Control (CCDC) Finds Two-drug Combination Therapies Effective in Improving Blood Pressure Control in Indians
NewsVoir New Delhi [India], July 30: A new study, entitled TOPSPIN, coordinated by the Centre for Chronic Disease Control (CCDC) New Delhi, in collaboration with the All India Institute of Medical Sciences (AIIMS) New Delhi, and Imperial College London, examined 1,981 patients with uncontrolled hypertension across 32 hospitals in India. The findings showed that three two-drug combination therapies - Amlodipine plus Perindopril, Amlodipine plus Indapamide, and Perindopril plus Indapamide - were equally effective and safe in lowering both ambulatory and office blood pressure. TOPSPIN is the first-ever randomised study to test the choice of first-line two-drug combination therapy in a single pill among South Asians. The study findings are published in Nature Medicine, one of the top medicine journals. South-Asians represent one-fourth of the world population, and India alone constitutes one-sixth of the global population. Hypertension is a public health crisis affecting over one billion adults worldwide, including over 300 million living in India. Innovative solutions are needed to curb the growing tide of high blood pressure, which is the single highest risk factor for global deaths, and which requires effective management solutions. Current guidelines widely recommend initiating treatment with two-drug combinations, preferably in a single-pill formulation, to enhance blood pressure control. However, the suitability of these combinations for the South-Asian population remains unknown, as there are no studies in this regard. The key takeaways are that all three combinations were equally effective in reducing blood pressure and were safe for patients. What did the TOPSPIN study find? - Blood pressure dropped significantly after 6 months, by around 14/8 mmHg when measured over 24 hours and about 30/14 mmHg in clinic settings. - Nearly 70% of patients reached the recommended blood pressure target below 140/90 mmHg, five times higher than India's current average control rate. - The pills were well-tolerated, with less than 3% of patients reporting side effects serious enough to stop treatment. What do the Study leaders say? "This study shows that a single daily pill with two drugs can be a simple and powerful way to manage blood pressure in Indian and South Asian patients," said Prof. Dorairaj Prabhakaran, Executive Director of CCDC and one of the study's lead authors. "These findings can help guide doctors and policymakers. If added to India's list of essential medicines and made available at primary health centres, these pills could greatly improve blood pressure control in the country." Prof. Ambuj Roy, Professor of Cardiology at AIIMS Delhi, added, "Nearly 70% of patients got their blood pressure under control, a huge improvement over the current national average. And the pills were safe and easy to use. This study gives clear guidance for better hypertension care." Prof. Neil Poulter, Professor at Imperial College London, emphasized the importance of studying how medicines work in different populations. "Just as earlier research in Africa showed different results, this study gives strong evidence on what works best in South Asians." The TOPSPIN study results could help improve treatment not only in India, but also for South Asians living around the world.
Fashion Value Chain
30-07-2025
- Health
- Fashion Value Chain
TOPSPIN Study by the Centre for Chronic Disease Control (CCDC) Finds Two-drug Combination Therapies Effective in Improving Blood Pressure Control in Indians
A new study, entitled TOPSPIN, coordinated by the Centre for Chronic Disease Control (CCDC) New Delhi, in collaboration with the All India Institute of Medical Sciences (AIIMS) New Delhi, and Imperial College London, examined 1,981 patients with uncontrolled hypertension across 32 hospitals in India. The findings showed that three two-drug combination therapies – Amlodipine plus Perindopril, Amlodipine plus Indapamide, and Perindopril plus Indapamide – were equally effective and safe in lowering both ambulatory and office blood pressure. TOPSPIN is the first-ever randomised study to test the choice of first-line two-drug combination therapy in a single pill among South Asians. The study findings are published in Nature Medicine, one of the top medicine journals. A doctor checking the blood pressure of a patient South-Asians represent one-fourth of the world population, and India alone constitutes one-sixth of the global population. Hypertension is a public health crisis affecting over one billion adults worldwide, including over 300 million living in India. Innovative solutions are needed to curb the growing tide of high blood pressure, which is the single highest risk factor for global deaths, and which requires effective management solutions. Current guidelines widely recommend initiating treatment with two-drug combinations, preferably in a single-pill formulation, to enhance blood pressure control. However, the suitability of these combinations for the South-Asian population remains unknown, as there are no studies in this regard. The key takeaways are that all three combinations were equally effective in reducing blood pressure and were safe for patients. What did the TOPSPIN study find Blood pressure dropped significantly after 6 months, by around 14/8 mmHg when measured over 24 hours and about 30/14 mmHg in clinic settings. Nearly 70% of patients reached the recommended blood pressure target below 140/90 mmHg , five times higher than India's current average control rate. The pills were well-tolerated, with less than 3% of patients reporting side effects serious enough to stop treatment. â What do the Study leaders say 'This study shows that a single daily pill with two drugs can be a simple and powerful way to manage blood pressure in Indian and South Asian patients,' said Prof. Dorairaj Prabhakaran, Executive Director of CCDC and one of the study's lead authors. 'These findings can help guide doctors and policymakers. If added to India's list of essential medicines and made available at primary health centres, these pills could greatly improve blood pressure control in the country.' Prof. Ambuj Roy, Professor of Cardiology at AIIMS Delhi, added, 'Nearly 70% of patients got their blood pressure under control, a huge improvement over the current national average. And the pills were safe and easy to use. This study gives clear guidance for better hypertension care.' Prof. Neil Poulter, Professor at Imperial College London, emphasized the importance of studying how medicines work in different populations. 'Just as earlier research in Africa showed different results, this study gives strong evidence on what works best in South Asians.' â The TOPSPIN study results could help improve treatment not only in India, but also for South Asians living around the world.
Hans India
28-07-2025
- Health
- Hans India
AIIMS-led study shows two-drug combination therapy effective in controlling high BP
New Delhi: Using a single pill comprising two blood pressure medicines is a safe and highly effective way to treat hypertension among South Asians, particularly Indians, finds a study led by the All India Institute of Medical Sciences (AIIMS), New Delhi. The study, in partnership with the Centre for Chronic Disease Control (CCDC) and Imperial College London, UK, compared three widely used drug combinations: amlodipine plus perindopril, amlodipine plus indapamide, and perindopril plus indapamide. The first randomised trial to test three different two-drug combination pills among South Asians involved over 1,200 patients with uncontrolled hypertension across 32 hospitals in India. "All three combinations worked equally well in reducing blood pressure and were safe for patients,' revealed the study, published in the journal Nature Medicine. The findings showed that either of the two-drug combinations led to a significant drop in blood pressure after 6 months -- by around 14/8 mmHg when measured over 24 hours and about 30/14 mmHg in clinic settings. 'Nearly 70 per cent of patients got their blood pressure under control, a huge improvement over the current national average. And the pills were safe and easy to use. This study gives clear guidance for better hypertension care,' said Dr Ambuj Roy, Professor of Cardiology at AIIMS Delhi. 'This study shows that a single daily pill with two drugs can be a simple and powerful way to manage blood pressure in Indian and South Asian patients,' said Dr Dorairaj Prabhakaran, Executive Director of CCDC. High blood pressure (hypertension) is the leading risk factor for death worldwide and affects over 300 million people in India alone. Treating it early and effectively can prevent heart attacks, strokes, and kidney failure. Doctors often recommend starting with two medications in one pill to control blood pressure better and help patients stick to treatment. But until now, no large study had tested which combinations worked best for South Asians, who make up a quarter of the world's population. The results revealed that nearly 70 per cent of patients with any of the dual drug therapy reached the recommended blood pressure target of below 140/90 mmHg -- five times higher than India's current average control rate. Less than 3 per cent of patients reported side effects serious enough to stop treatment. 'These findings can help guide doctors and policymakers. If added to India's list of essential medicines and made available at primary health centres, these pills could greatly improve blood pressure control in the country,' Prabhakaran said.
